A new chemical tool (C0036E08) supports the role of adenosine A2B receptors in mediating human mast cell activation

Asthma is a chronic inflammatory disease of the airways that involves many cell types, amongst which mast cells are known to be important. Adenosine, a potent bronchoconstricting agent, exerts its ability to modulate adenosine receptors of mast cells thereby potentiating derived mediator release, histamine being one of the first mediators to be released. The heterogeneity of sources of mast cells and the lack of highly potent ligands selective for the different adenosine receptor subtypes have been important hurdles in this area of research. In the present study we describe compound C0036E08, a novel ligand that has high affinity (pKi 8.46) for adenosine A2B receptors, being 9 times, 1412 times and 3090 times more selective for A2B receptors than for A1, A2A and A3 receptors, respectively. Compound C0036E08 showed antagonist activity at recombinant and native adenosine receptors, and it was able to fully block NECA-induced histamine release in freshly isolated mast cells from human bronchoalveolar fluid. C0036E08 has been shown to be a valuable tool for the identification of adenosine A2B receptors as the adenosine receptors responsible for the NECA-induced response in human mast cells. Considering the increasing interest of A2B receptors as a therapeutic target in asthma, this chemical tool might provide a base for the development of new anti-asthmatic drugs.